Astellas Pharma Gmbh

Mitobridge, Inc.

Junko Maeda

Akio Kamikawa

Toru Asano

Koji Kato

Junji Sato

Ryushi Seo

Kenji Negoro

Wataru Hamaguchi

Sunao Imada

Hirokazu Kubota

Masakatsu Kawakami

Ikumi Kuriwaki

Ryosuke Munakata

Kazuyuki Hattori

Jeffrey Ciavarri

Fumie Takahashi

Yoshihiro Kozuki

Yumi Yamashita

Masahiko Shiwaku

Hidehiko Fukahori

Kai Kitamura

Kenichi Kakefuda

Masahiko (deceased) Shiwaku

[Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Aryl alkynamide derivatives

Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3K&#x3b4; selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3K&#x3b4; selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.

Heterocyclic compound

Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I): wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.

Triarylcarboxylic acid derivative

Growing community of inventors

Tokyo, Japan

Junko Maeda